Equities analysts expect that Phio Pharmaceuticals Corp (NASDAQ:PHIO) will announce earnings of ($0.09) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Phio Pharmaceuticals’ earnings. Phio Pharmaceuticals posted earnings of ($0.10) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 10%. The firm is scheduled to announce its next earnings results on Wednesday, March 25th.

On average, analysts expect that Phio Pharmaceuticals will report full-year earnings of ($0.36) per share for the current financial year. For the next fiscal year, analysts forecast that the business will report earnings of ($0.35) per share. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Phio Pharmaceuticals.

Phio Pharmaceuticals (NASDAQ:PHIO) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, hitting analysts’ consensus estimates of ($0.08).

A hedge fund recently raised its stake in Phio Pharmaceuticals stock. Citadel Advisors LLC lifted its holdings in shares of Phio Pharmaceuticals Corp (NASDAQ:PHIO) by 148.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 85,621 shares of the company’s stock after purchasing an additional 51,216 shares during the quarter. Citadel Advisors LLC owned 0.36% of Phio Pharmaceuticals worth $33,000 at the end of the most recent quarter. 5.67% of the stock is currently owned by hedge funds and other institutional investors.

PHIO stock traded down $0.03 during trading on Monday, hitting $0.24. 421,200 shares of the stock traded hands, compared to its average volume of 350,896. Phio Pharmaceuticals has a one year low of $0.19 and a one year high of $0.52. The stock has a market cap of $8.19 million, a price-to-earnings ratio of -0.23 and a beta of 1.63. The company has a 50 day simple moving average of $0.24 and a 200 day simple moving average of $0.35. The company has a current ratio of 5.87, a quick ratio of 5.87 and a debt-to-equity ratio of 0.05.

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye.

Featured Article: What is Compound Interest?

Get a free copy of the Zacks research report on Phio Pharmaceuticals (PHIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.